title: Prevention of systemic and regional haemodynamic alterations, hypercreatininemia, hyperuremia and hyperphosphatemia by losartan in hypertension with acute renal failure.
abstract: Patients with pre-existing hypertension are at a particular risk of fatal outcome due to acute renal failure (ARF). We investigate the effects of angiotensin II type-1 receptor blocker (ARB) losartan, on haemodynamics and biochemical parameters in adult male spontaneously hypertensive rats (SHR) with ischemia/reperfusion ARF. SHR were randomly selected in three experimental groups: sham-operated group (SHAM), ARF group, and ARF+LOS group (losartan, 10 mg/kg/b.w. given by infusion during the period of three hours after reperfusion). Beside the improvement of systemic haemodynamics 24 h after reperfusion, losartan significantly increased renal blood flow (RBF: 19.33±3.29 ml/min/kg vs. 8.03±1.04 ml/min/kg, p<0.05) and decreased renal vascular resistance (RVR) compared to ARF (8.85±1.21 mmHg × min × kg/ml vs. 19.90±2.35 mmHg × min × kg/ml, p<0.001). Plasma creatinine (Pcr), urea (Pu) and phosphates (Pphos) were significantly reduced in ARF+LOS group compared to ARF group (Pcr: 99.11±14.56 μmol/l vs. 242.71±20.25 μmol/l, p<0.001; Pu: 33.72±4.69 mmol/l vs. 61.90±3.93 mmol/l, p<0.001; 2.7±0.42 mmol/l vs. 5.57±0.61 mmol/l, p<0.01). Our results demonstrate that losartan improves systemic and regional haemodynamic and biochemical parameters in hypertension with ARF.
authors.affiliation: University of Belgrade, Department of Cardiovascular Physiology, Institute for Medical Research Dr. Subotia 4 PO BOX 102 11129, Belgrade, Serbia. ivmilan@imi.bg.ac.rs
authors.forename: Milan
authors.initials: M
authors.lastname: Ivanov
authors.forename: N
authors.initials: N
authors.lastname: Mihailovic-Stanojevic
authors.forename: J
authors.initials: J
authors.lastname: Grujic Milanovic
authors.forename: D
authors.initials: D
authors.lastname: Jovovic
authors.forename: Z
authors.initials: Z
authors.lastname: Miloradovic
mesh_terms: D058186:Acute Kidney Injury / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000818:Animals; D003404:Creatinine / Q000097:blood*; D006439:Hemodynamics / Q000187:drug effects; D054559:Hyperphosphatemia / Q000097:blood / Q000517:prevention & control*; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D019808:Losartan / Q000494:pharmacology*; D008297:Male; D011897:Random Allocation; D051381:Rats; D011918:Rats, Inbred SHR; D012079:Renal Circulation / Q000187:drug effects; D014508:Urea / Q000097:blood*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D014508:Urea; D003404:Creatinine; D019808:Losartan